COSTEM 2023 | Emerging options for patients with MCL who relapse after a frontline BTKi
Georg Hess, MD, University Medical Center Mainz, Mainz, Germany, discusses the currently available and emerging options for the treatment of mantle cell lymphoma (MCL) in patients who relapse after exposure to frontline BTK inhibitors (BTKis). This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, ADC-Therapeutics, AstraZenaeca, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, Miltenyi, Novartis, Roche
Honoraria: Abbvie, AstraZeneca, Beigene, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, Roche
Research Funding: Abbvie, Gilead/Kite, Incyte, Janssen, Morphosys, Roche
Patents and Royalties: not applicable
Membership on an entity’s Board of Directors or advisory committees: not applicable
Discussion of off-label drug use: not applicable
Travel grants: Gilead/Kite, Janssen
